Hatz AI Lands $24M Series A in NYC's Latest Funding Roundup

Hatz AI raised $24 million in Series A funding on 11/12/2026, the largest deal in the latest New York City tech funding cycle. Nadia Partners led the round, with Vestigo Ventures and The Private Shares Fund participating.

The company has now raised $26.5 million in total reported equity funding. That means the Series A accounts for more than 90% of everything Hatz AI has banked since its founding.

What does Hatz AI actually do?

Hatz AI builds a platform that lets managed service providers sell and manage AI services for small and medium-sized businesses. The company was founded by Jimmy Hatzell and Aidan Kehoe in 2023.

The bet from Nadia Partners is straightforward: SMBs want AI capabilities but lack the in-house expertise to deploy them, and managed service providers already own those customer relationships. Hatz AI sits in the middle, turning AI into a product channel partners can resell.

Takeaway: a 2023-founded company just converted a two-year track record into a $24M check.

Duet raises $15M to help nurse practitioners go independent

Duet, a healthtech network that helps nurse practitioners open and run their own primary care practices, raised $15 million in Series A funding. Kairos HQ led the round, with Lerer Hippeau participating.

Founder Jonathan Goldberg launched Duet in 2023. The company has now raised $22.5 million in total reported equity funding — meaning this Series A adds two-thirds of its lifetime capital in a single transaction.

Lerer Hippeau's involvement is notable. The firm is one of New York's most active early-stage investors, and its continued participation points to confidence in the practitioner-independence model rather than a one-off seed bet.

Takeaway: Duet is betting that primary care's future runs through nurse practitioners who own their practices, not hospital systems.

BioWraptor secures $1.5M pre-seed

BioWraptor, a biotech company that stabilizes fragile biomolecules at room temperature, raised $1.5 million in pre-seed funding.

The investor list is a mix of funds and angels: Anima x Alpha Star, SNOCAP, NY Ventures, Pascal Marguet, Berangere Marguet, Ryan Jeffery, and Greg Haar. Maeva Coste and Jen Laws founded the company.

The technical problem BioWraptor targets is cold chain dependency. Biomolecules that normally require refrigeration degrade at ambient temperatures, and a stabilization technology that removes that constraint could cut storage and distribution costs across diagnostics and therapeutics.

Takeaway: a $1.5M pre-seed won't prove the science, but it buys the founders the runway to try.

What the 11/12/2026 numbers say

The three deals total $40.5 million in new capital for NYC startups across AI, healthtech, and biotech:

• Hatz AI — $24M Series A, led by Nadia Partners, total funding now $26.5M
• Duet — $15M Series A, led by Kairos HQ with Lerer Hippeau, total funding now $22.5M
• BioWraptor — $1.5M pre-seed, backed by Anima x Alpha Star, SNOCAP, NY Ventures, and four angel investors

Two of the three rounds went to companies founded in 2023, both hitting Series A stage within roughly three years. Series A checks of $15M and $24M for companies at that age signal that NYC investors are still paying up for traction in AI distribution and healthcare infrastructure.

The report will be updated throughout the day as additional fundings are confirmed — so the $40.5M total may yet grow.